Media stories about Collegium Pharmaceutical (NASDAQ:COLL) have trended somewhat positive on Thursday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 45.0327085717021 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Traded Higher Than Its 50 Day Average – First News 24 (firstnewspaper24.com)
- Collegium Pharmaceutical, Inc. (COLL) registers a price change of -1.02% while BioDelivery Sciences International … – Stocks Gallery (stocksgallery.com)
- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Sees Heavy Trading Volume with 499K Shares Changing Hands – First News 24 (firstnewspaper24.com)
- Where Relative Volume Stands?: Collegium Pharmaceutical Inc (NASDAQ: COLL) – Alpha Beta Stock (alphabetastock.com)
- Stocks Entering Oversold Region: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – NASDAQ Times (nasdaqtimes.com)
COLL has been the topic of a number of research analyst reports. Piper Jaffray Companies restated a “buy” rating and issued a $14.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. BidaskClub lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Jefferies Group LLC restated a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Finally, HC Wainwright initiated coverage on shares of Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a “buy” rating and a $21.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $20.00.
Shares of Collegium Pharmaceutical (COLL) traded up 0.08% during trading on Thursday, reaching $11.84. 428,510 shares of the company were exchanged. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $18.67. The stock has a 50-day moving average price of $10.74 and a 200-day moving average price of $10.74. The stock’s market capitalization is $350.06 million.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $4.07 million. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. Analysts forecast that Collegium Pharmaceutical will post ($3.00) EPS for the current year.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.